Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06859450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Local Antibiotic Delivery for Community Acquired Pneumonia

Study acronym: LANDCAP-1
StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 10, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 1 of 6 entries
    • Study description expanded, about 13 words
    • Study title shortened, about 3 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.
Trial Details
NCT Number NCT06859450
Lead Sponsor Copenhagen Respiratory Research
Conditions
(from sponsor)		 Community Acquired Pneumonia (CAP)
Related terms Asthma, Community-Acquired Pneumonia, Pulmonary Disease, Chronic Obstructive
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov